Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA))), a global leader in health technology, today announced Clinical Trial Accelerator on Philips HealthSuite. This new tailored set of capabilities allows life science organizations to integrate, analyze and store clinical and patient-reported data from multiple sources, providing actionable insights for better, faster decision-making.

Life science organizations face continued pressure to run more efficient, cost-effective clinical trials. Empowering patients and making it easier for them to stay connected and contribute to a trial can have a significant impact on compliance rates and overall success. At the same time, collecting data and identifying actionable insights while ensuring the security and compliance of patient information is key. Clinical Trial Accelerator is designed to address these challenges, helping life science organizations reach their goals faster and supporting greater flexibility in trial design.

"Philips HealthSuite already provides cloud-based services and tools to a wide array of healthcare organizations, and with Clinical Trial Accelerator we have created a tailored set of capabilities to support life science organizations," said Dale Wiggins, General Manager for the HealthSuite digital platform at Philips. "Our innovative, flexible cloud platform leverages our global healthcare capabilities and is supported by our compliance, security and interoperability expertise."

Tailored capabilities to accelerate clinical trials
Other HealthSuite capabilities include an AI Analytics Workbench for enhanced decision making and standards-based interoperability for Digital Imaging and Communication in Medicine (DICOM) data, as well as the HealthSuite Clinical Data Lake, a new scalable micro-service that acts as a centralized big data repository for high-volume clinical data collection studies and includes controls to curate and manage data in a manner that addresses regulatory requirements.

These HealthSuite capabilities offer companies cloud-based services and technical tools that meet privacy, security and regulatory requirements that they can use to develop and run a new generation of connected healthcare applications. Unlike other digital platforms, HealthSuite is purpose-built to solve the complex challenges of healthcare, featuring capabilities to manage device data, collect personal and health data, store and share data securely, analyze data, build and deploy AI models, and create solutions on the cloud.

In addition, these HealthSuite capabilities power a wide range of both Philips and 3^rd party connected healthcare applications in areas including image-guided therapy, sleep and respiratory care, ophthalmology, telehealth and self-medication. For 3^rd party collaborations, Philips is the provider of the relevant cloud-based healthcare IT infrastructure and is not involved in the commercialization of the products and services of these companies. More information on Philips HealthSuite can be found at www.philips.com/healthsuite.

Mark Groves
Philips Global Press Office
Tel: +31 631 639 916
Email: [email protected]
Twitter: mark_groves

Royal Philips (NYSE:PHG, AEX: PHIA))) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 81,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

• Philips Care Orchestrator for sleep and respiratory therapy
• Philips HealthSuite logo